Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Unknown

PEN-866 in Patients With Advanced Solid Malignancies

A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies

Outcome
Outcome unknown
Phase
Phase 1 / Phase 2
Status
Unknown
Study type
Interventional
Start
29 August 2017
Listed end
June 2023
Enrollment
340 participants
Sites
16
Primary outcomes
Phase 1a and 1b : Incidence of Dose-Limiting Toxicities (DLTs); All Phases: Incidence of treatment related adverse events (Safety and tolerability); Phase 2a: Efficacy of PEN-866 in patients with SCLC using best overall response rate; Phase 2a: Efficacy of PEN-866 in patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma using best overall response rate; Phase 2a: Efficacy of PEN-866 in patients with pancreatic adenocarcinoma using Disease Control Rate (DCR)
Sponsor type
Industry
Results posted
No
Last update
17 February 2022

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.

Detailed description public domain (ClinicalTrials.gov)

Phase 1a will employ an adaptive model guided with overdose control principle to make dose recommendations and estimate the maximum tolerated dose (MTD) of PEN-866 (single agent). Phase 1b will employ a standard 3 + 3 design to make dose recommendations and estimate the MTD of PEN-866 in combination therapy. Phase 2a (single agent) will assess the safety, tolerability, pharmacokinetic, and pharmacodynamics profile of PEN-866 (single agent) at the recommended Phase 2 dose determined at the conclusion of Phase 1a in patients with advanced solid malignancies.